Randomized, Double-blind, Cross-over Study in COPD Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder.
Phase of Trial: Phase I
Latest Information Update: 05 Jun 2014
At a glance
- Drugs Ciprofloxacin (Primary)
- Indications Bacterial infections; Respiratory tract infections
- Focus Pharmacokinetics
- Sponsors Bayer
- 05 Oct 2010 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
- 05 Oct 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 05 Aug 2010 New trial record